Comparison · NCT05593770-da8be995
Fostamatinib vs Placebo: 60-day Mortality
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Fostamatinib vs Placebo: 60-day Mortality. Trial comparisons, record NCT05593770-da8be995. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05593770-da8be995
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0769 | 0.0137 | 0.333 | wilson | |
| Risk in group 2 | 0.167 | 0.047 | 0.448 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0897 | -0.378 | 0.193 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.462 | 0.0477 | 4.46 | log | |
| Odds ratio, group 1 over group 2 | 0.417 | 0.0328 | 5.3 | log | |
| Number needed to treat, for one fewer participant with the outcome on Fostamatinib than on Placebo | 11.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Fostamatinib | An investigational oral spleen tyrosine kinase inhibitor.~Fostamatinib: Fostamatinib100-150mg orally twice daily for 14 days or 28 doses. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses. | 1 | 13 | OG000 |
| Group 2 | Placebo | Orange film-coated, plain, bioconvex tablets for fostamatinib.~For the purposes of interim and final analyses, the route and frequency of placebo will be ignored, and all placebo participants will be pooled together as a single group. In comparing an active drug versus placebo, only those placebo participants that were eligible for the active drug will be included.~Placebo: Orange film-coated, plain bioconvex tablets orally twice daily for 14 days or 28 doses for fostamatinib. Study medication will be continued as an outpatient if the patient is discharged prior to completing 28 doses. | 2 | 12 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- 60-day Mortality
- Description
- Number of patients who have died at Day 60
- Time frame
- Day 60
- Population
- Participants who lacked outcome data were not included in the analysis. Ineligible participants or those who didn't receive the treatment were excluded.
Source ClinicalTrials.gov
Trial
- Title
- International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response
- NCT number
- NCT05593770
- Phases
- PHASE2, PHASE3
- Conditions
- COVID-19, SARS-CoV2 Infection, Coronavirus Infection
- Interventions
- Fostamatinib, Placebo
- Lead sponsor
- NEAT ID Foundation
- Results first posted
- 2024-11-05
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05593770?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05593770-da8be995